Researchers from the Indian Institute of Technology Madras (IIT Madras) in Chennai, India, along with experts from Monash University and Deakin University in Australia, have developed a new precision nanoinjection platform for breast cancer treatment. This innovative system aims to significantly improve patient safety and treatment effectiveness by delivering drugs directly into cancer cells, thereby minimizing damage to surrounding healthy tissues.
The newly developed platform uniquely combines two advanced components. It utilizes nanoarchaeosome-based drug encapsulation for precise drug packaging. It then uses silicon nanotube (SiNT)-based technology for intracellular delivery. This dual approach is critical for minimizing widespread drug exposure, a major challenge with conventional cancer therapies like chemotherapy that often harm non-cancerous cells throughout the body.
Breast cancer remains one of the leading causes of mortality among women globally. Traditional treatments frequently cause severe side effects because anticancer drugs affect healthy tissues alongside cancerous ones.
The research team specifically designed this nanoinjection system to deliver doxorubicin, a potent anticancer drug. Doxorubicin is encased within thermally stable nanoarchaeosomes. These microscopic, heat-resistant carriers protect the drug until it reaches its target. The drug-loaded nanoarchaeosomes are then precisely injected into individual cancer cells using vertically aligned silicon nanotubes. This targeted delivery ensures maximum impact on cancer cells while sparing healthy tissue.
Experimental Results and Findings
Experimental results demonstrated the Nanoarchaeosome-Doxorubicin–Silicon Nanotube (NAD-SiNT) platform’s effectiveness. It induced strong cytotoxic effects, meaning it effectively killed MCF-7 breast cancer cells. Crucially, the system did not harm healthy fibroblasts, which are normal connective tissue cells, during testing. This precision is vital for reducing debilitating side effects for patients.
The NAD-SiNT system proved significantly more potent than free doxorubicin. It achieved a 23-fold lower inhibitory concentration, meaning far less drug is required to achieve the same cancer-killing effect. The platform also successfully reduced angiogenesis, which is the growth of new blood vessels that feed tumors. Additionally, it provided sustained drug release for an extended period, lasting up to 700 hours.
These significant findings were published in the peer-reviewed journal “Advanced Materials Interfaces.” The study’s co-authors include Kaviya Vijayalakshmi Babunagappan, Subastri Ariraman, Jann Harberts, Vimalraj Selvaraj, Mukilarasi Bedatham, Narendran Sekar, Nicolas H Voelcker, Roey Elnathan, and Swathi Sudhakar.
Researchers further noted the silicon nanotube-based design possesses inherent biocompatibility, meaning it is safe and compatible with biological systems. Its scalability also suggests it can be manufactured in larger quantities. These attributes make the platform a promising candidate for future clinical translation into practical medical applications.
Addressing Global Health Needs
Swathi Sudhakar, an assistant professor and faculty advisor for clinical engineering in IIT Madras’s Department of Applied Mechanics and Biomedical Engineering, highlighted the research’s profound implications. Sudhakar stated the platform holds the potential to revolutionize healthcare delivery in low- and middle-income countries like India. In these regions, access to advanced cancer therapies is often severely constrained by high costs.
Sudhakar added that this targeted approach offers two key benefits. It could significantly reduce the overall expense of cancer treatment, making it more accessible to a wider population. It also holds the potential to vastly improve patients’ quality of life by minimizing debilitating side effects associated with current treatments. Sudhakar further suggested the system could be adapted for use against other forms of cancer, broadening its therapeutic impact.
Future Outlook and Collaboration
Roey Elnathan, from Deakin University’s Faculty of Health, outlined the critical next phases of development for the platform. Elnathan described the current work as laying the essential foundation for a modular drug delivery system. The immediate priority is in vivo validation, which involves testing the platform in living organisms to confirm its safety and efficacy. Researchers also plan to evaluate its effectiveness across various cancer types, moving beyond breast cancer.
Professor Nicolas H Voelcker, based at the Monash Institute of Pharmaceutical Sciences, provided a timeline for the technology’s real-world adoption. Voelcker anticipates the patented drug delivery technology will move from research to practical clinical application within the next five years, reaching patients who need it.
The research received crucial support from several key organizations. These include the IIT Madras–Deakin joint research initiative, the Alexander von Humboldt Foundation, and the Australian Research Council (ARC).